References
- Bourrie M, Meunier V, Berger Y, Fabre G. (1996). Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321–32
- Boxenbaum H. (1982). Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201–27
- Boxenbaum H. (1984). Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev 15:1071–121
- Buonamici S, Williams J, Morrissey M, et al. (2010). Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2:51ra70 (1--8)
- Campbell V, Nadesan P, Wang Y, et al. (2011). Direct targeting of the Hedgehog pathway in primary chondrosarcoma xenografts with the Smoothened inhibitor IPI-926. Poster Presented at the American Association for Cancer Research Annual Meeting, Orlando, FL
- Chappell WR, Mordenti J. (1991). Extrapolation of toxicological and pharmacologic data from animals to humans. Adv Drug Res 20: 1–116
- Chen MH, Wilson CW, Li YJ, et al. (2009). Cilium-independent regulation of Gli protein function by Sufu in Hedgehog signaling is evolutionarily conserved. Genes Dev 23:1910–28
- Cooper MK, Porter JA, Young KE, Beachy PA. (1998). Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 280:1603–7
- Eggenschwiler JT, Anderson KV. (2007). Cilia and developmental signaling. Annu Rev Cell Dev Biol 23:345–73
- FDA. (2012). Draft Guidance Document, Drug Interaction Studies – Study Design, Data Analysis, Implications for Dosing and Labeling Recommendations
- Feldmann G, Fendrich V, McGovern K, et al. (2008). An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther 7:2725–35
- Giannetti AM, Wong H, Dijkgraaf GJ, et al. (2011). Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449). J Med Chem 54:2592–601
- Gibaldi M, Perrier D. (1982). Pharmacokinetics. 2nd ed. New York (NY): Marcel Dekker
- Goodrich LV, Milenković L, Higgins KM, Scott MP. (1997). Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 277:1109–13
- Hahn H, Wicking C, Zaphiropoulous PG, et al. (1996). Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85:841–51
- Humke EW, Dorn KV, Milenkovic L, et al. (2010). The output of Hedgehog signaling is controlled by the dynamic association between Suppressor of Fused and the Gli proteins. Genes Dev 24:670–82
- Israili ZH, Dayton PG. (2001). Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev 33:161–235
- Jiang J, Hui C-C. (2008). Hedgehog signaling in development and cancer. Dev Cell 15:801–12
- Jimeno A, Weiss GJ, Miller Jr WH, et al. (2013). Phase 1 study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res, submitted
- Johnson RLR, Alana L, Xie J, et al. (1996). Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 272:1668–71
- Lee MJ, Hatton BA, Villavicencio EH, et al. (2012). Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. Proc Natl Acad Sci USA 109:7859–64
- Lee Y, Miller HL, Jensen P, et al. (2003). A molecular fingerprint for medulloblastoma. Cancer Res 63:5428–37
- Obach RS, Walsky RL, Venkatakrishnan K, et al. (2006). The utility of in vitro cytochrome P450 inhibition data in the prediction of drug--drug interactions. J Pharmacol Exp Ther 316:336–48
- Obach RS, Walsky RL, Venkatakrishnan K. (2007). Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drugdrug interactions. Drug Metab Disp 35:246–55
- Pasca Di Magliano M, Hebrok M. (2003). Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer 3:903–11
- Raffel C, Jenkins RB, Frederick L, et al. (1997). Sporadic medulloblastomas contain PTCH mutations. Cancer Res 57:842–5
- Rohatgi R, Milenković L, Scott MP. (2007). Patched1 regulates hedgehog signaling at the primary cilium. Science 317:372–6
- Rudin CM, Hann CL, Laterra J, et al. (2009). Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 361:1173–8
- Rudorfer MV, Potter WZ. (1999). Metabolism of tricyclic antidepressants. Cell Mol Neurobiol 19:373–409
- Segal IH. (1975). Enzyme kinetics: behavior and analysis of rapid equilibrium and steady-state enzyme systems. New York: John Wiley & Sons, Inc
- Taipale J, Chen JK, Cooper MK, et al. (2000). Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 406:1005–9
- Tiet TD, Hopyan S, Nadesan P, et al. (2006). Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. Am J Pathol 168:321–30
- Tremblay MR, Lescarbeau A, Grogan MJ, et al. (2009). Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem 52:4400–18
- Tremblay MR, Nevalainen M, Nair SJ, et al. (2008). Semisynthetic cyclopamine analogues as potent and orally bioavailable hedgehog pathway antagonists. J Med Chem 51:6646–9
- Von Hoff DD, Lorusso PM, Rudin CM, et al. (2009). Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361:1164–72
- Yauch RL, Gould SE, Scales SJ, et al. (2008). A paracrine requirement for hedgehog signalling in cancer. Nature 455:406–10